Inventor · disambiguated record
Russell P. Rother
Also filed as: ROTHER RUSSELL · ROTHER RUSSELL P
38 granted patents·32 pending applications·908 citations·filing 1994–2024
98Inventor score
Top patents by PatentIndex Score
70 records- 0197US9085623B2Therapeutic methods using anti-CD200 antibodiesROTHER RUSSELL P·Filed 2011·Granted Jul 21, 2015·50 cites·11 claims
- 0296US9718880B2Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complementALEXION PHARMA INC·Filed 2016·Granted Aug 1, 2017·17 cites·3 claims
- 0396US7393648B2Hybrid antibodiesALEXION PHARMA INC·Filed 2003·Granted Jul 1, 2008·86 cites·15 claims
- 0496US6355245B1C5-specific antibodies for the treatment of inflammatory diseasesALEXION PHARMA INC·Filed 1995·Granted Mar 12, 2002·465 cites·23 claims
- 0595US10703809B1Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complementALEXION PHARMA INC·Filed 2020·Granted Jul 7, 2020·3 cites·29 claims
- 0695US9732149B2Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complementALEXION PHARMA INC·Filed 2016·Granted Aug 15, 2017·15 cites·1 claims
- 0795US9725504B2Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complementALEXION PHARMA INC·Filed 2016·Granted Aug 8, 2017·14 cites·10 claims
- 0895US9011852B2Anti-C5a antibodiesROTHER RUSSELL P·Filed 2011·Granted Apr 21, 2015·25 cites·18 claims
- 0994US9447176B2Methods and compositions for treating complement-associated disordersROTHER RUSSELL P·Filed 2009·Granted Sep 20, 2016·21 cites·4 claims
- 1094US9221901B2Methods of treating complement-associated disorders with anti-C5a antibodiesALEXION PHARMA INC·Filed 2015·Granted Dec 29, 2015·11 cites·16 claims
- 1193US9771418B2Methods for treating complement-associated disordersALEXION PHARMA INC·Filed 2016·Granted Sep 26, 2017·8 cites·4 claims
- 1293US9371378B1Anti-C5a antibodiesALEXION PHARMA INC·Filed 2016·Granted Jun 21, 2016·7 cites·10 claims
- 1392US10590189B2Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complementALEXION PHARMA INC·Filed 2017·Granted Mar 17, 2020·7 cites·8 claims
- 1491US9309310B2Nucleic acids encoding anti-C5a antibodiesALEXION PHARMA INC·Filed 2015·Granted Apr 12, 2016·7 cites·20 claims
- 1590US11807678B2Methods and compositions for treating complement-associated disordersALEXION PHARMA INC·Filed 2019·Granted Nov 7, 2023·2 cites·3 claims
- 1690US2025092123A1Methods and compositions for treating complement-associated disordersALEXION PHARMA INC·Filed 2024·Application pending·0 cites
- 1789US9469690B2Methods of treating complement-associated disorders with anti-C5a antibodiesALEXION PHARMA INC·Filed 2016·Granted Oct 18, 2016·4 cites·14 claims
- 1889US9434784B1Nucleic acids encodng anti-C5A antibodiesALEXION PHARMA INC·Filed 2016·Granted Sep 6, 2016·4 cites·27 claims
- 1987US8282924B2Hybrid antibodiesROTHER RUSSELL P·Filed 2011·Granted Oct 9, 2012·5 cites·18 claims
- 2087US8252285B2Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responsesROTHER RUSSELL P·Filed 2008·Granted Aug 28, 2012·8 cites·30 claims
- 2187US5847082ATerminal complement inhibitor fusion proteinsALEXION PHARMA INC·Filed 1995·Granted Dec 8, 1998·60 cites·4 claims
- 2285US10450370B2Anti-C5a antibodiesALEXION PHARMA INC·Filed 2018·Granted Oct 22, 2019·2 cites·20 claims
- 2385US8945565B2Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodiesROLLINS SCOTT·Filed 2010·Granted Feb 3, 2015·8 cites·18 claims
- 2485US8637014B2Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responsesROTHER RUSSELL P·Filed 2012·Granted Jan 28, 2014·7 cites·29 claims
- 2584US9963503B2Methods of producing anti-C5a antibodiesALEXION PHARMA INC·Filed 2016·Granted May 8, 2018·2 cites·2 claims
- 2684US2023159627A1Anti-c5a antibodiesALEXION PHARMA INC·Filed 2022·Application pending·0 cites
- 2783US9068001B2Anti-P-selectin antibodiesROLLINS SCOTT·Filed 2011·Granted Jun 30, 2015·8 cites·15 claims
- 2881US11407821B2Anti-C5A antibodiesALEXION PHARMA INC·Filed 2019·Granted Aug 9, 2022·0 cites·24 claims
- 2981US9862767B2Therapeutic methods using anti-CD200 antibodiesALEXION PHARMA INC·Filed 2015·Granted Jan 9, 2018·3 cites·13 claims
- 3081USRE46323EAntibodies to OX-2/CD200 and uses thereof in inhibiting immune responsesALEXION PHARMA INC·Filed 2008·Granted Feb 28, 2017·3 cites·40 claims
- 3181US7399594B2Hybrid antibodiesALEXION PHARMA INC·Filed 2002·Granted Jul 15, 2008·7 cites·21 claims
- 3277US10126293B2Reagents and methods for detecting PNH type II white blood cells and their identification as risk factors for thrombotic disordersALEXION PHARMA INC·Filed 2017·Granted Nov 13, 2018·1 cites·4 claims
- 3377US7927817B2Hybrid antibodiesALEXION PHARMA INC·Filed 2008·Granted Apr 19, 2011·1 cites·26 claims
- 3474US8067167B2Hybrid antibodiesROTHER RUSSELL P·Filed 2010·Granted Nov 29, 2011·1 cites·20 claims
- 3572US2020392216A1Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complementALEXION PHARMA INC·Filed 2020·Application pending·0 cites
- 3670US9388235B2Methods and compositions for the treatment of antibody mediated neuropathiesHALSTEAD SUSAN·Filed 2007·Granted Jul 12, 2016·7 cites·16 claims
- 3770US5871997AMethods and compositions for protecting retroviral vector particles and producer cells from inactivation by complement via reduction of the expression or recognition of galactose alpha (1,3) galactosyl epitopesALEXION PHARMA INC·Filed 1995·Granted Feb 16, 1999·19 cites·11 claims
- 3870US2020140531A1Methods for treating complement-associated disordersALEXION PHARMA INC·Filed 2019·Application pending·0 cites
- 3969US2010068202A1Method of treating hemolytic diseaseALEXION PHARMA INC·Filed 2009·Application pending·0 cites
- 4065US11112402B2Reagents and methods for detecting PNH type II white blood cells and their identification as risk factors for thrombotic disordersALEXION PHARMA INC·Filed 2018·Granted Sep 7, 2021·0 cites·19 claims
- 4165US2017369562A1Methods for treating complement-associated disordersALEXION PHARMA INC·Filed 2017·Application pending·0 cites
- 4264US2014286962A1Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disordersALEXION PHARMA INC·Filed 2014·Application pending·0 cites
- 4363US2009220508A1Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of ComplementALEXION PHARMA INC·Filed 2007·Application pending·0 cites
- 4462US2017015740A1Methods for treating complement-associated disordersALEXION PHARMA INC·Filed 2016·Application pending·0 cites
- 4561US2012237515A1Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complementBELL LEONARD·Filed 2012·Application pending·0 cites
- 4661US2016319004A1Methods and compositions for treating complement-associated disordersALEXION PHARMA INC·Filed 2016·Application pending·0 cites
- 4761US2024209097A1Treatment regimensNOVARTIS AG·Filed 2023·Application pending·0 cites
- 4858US2005169921A1Method of treating hemolytic diseaseFiled 2004·Application pending·0 cites
- 4958US2012308559A1Method of treating hemolytic diseaseBELL LEONARD·Filed 2011·Application pending·0 cites
- 5057US2005191298A1Method of treating hemolytic diseaseFiled 2005·Application pending·0 cites
Showing the top 50 of 70 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Russell P. Rother files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →